Skip to main content
. Author manuscript; available in PMC: 2016 Aug 19.
Published in final edited form as: Sci Signal. 2016 Feb 2;9(413):ra12. doi: 10.1126/scisignal.aad3210

Fig. 7.

Fig. 7

ABL kinases are required for TAZ and STAT5 signaling in breast cancer cells.

(A–C) Immunoblots using the indicated antibodies were performed on whole-cell lysates of 1833 and SCP28 cells. (D) Immunoblots were performed on whole-cell lysates (pSTAT5, STAT5, tubulin), or conditioned medium (MMP1, IL6, TNC). (E) Immunoblots were performed on whole-cell lysates (pSTAT5, STAT5, tubulin), or conditioned medium (MMP1, IL6, TNC) of parental 1833 and SCP28 cells. (F) Immunoblotting using the indicated antibodies were performed on whole-cell lysates (pSTAT5, STAT5, tubulin), or conditioned medium (MMP1, IL6, TNC) of 1833 cells. For (A–F), N=3 blots. (G–H) Bioluminescent images (G) of representative mice at day 25 after intracardiac injection of 1833 cells. Quantification (H) of bone metastasis. N=5 mice/group. * p<0.05; **p<0.01; ***p<0.001. p value was calculated using One-Way ANOVA followed by Tukey’s HSD. (I–J) Bioluminescent images (I) and quantification (J) of bone metastasis from representative mice at day 25 after intracardiac injection of 1833 cells transfected with control (NS) or shRNAs against STAT5 and TAZ (shSTAT5/shTAZ). N=8 mice/group. (K) Immunoblots were performed on whole cell lysate. N=3 blots.